Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-7-16
pubmed:abstractText
It has recently been shown that the antianginal drug bepridil (BEP) activates mitochondrial ATP-sensitive potassium (mitoK(ATP)) channels and thus confers cardioprotection. Our aim was to investigate whether BEP could induce preconditioning in cultured rat cortical neurons. Although BEP depolarized isolated and in situ mitochondria and increased reactive oxygen species generation, no acute protection was observed. However, a 3-day BEP-treatment elicited dose-dependent delayed neuroprotection against 180 min of oxygen-glucose deprivation (cell viability: untreated, 52.5 +/- 0.85%; BEP 1 micromol/L, 59.6 +/- 1.53%*; BEP 2.5 micromol/L, 71.9 +/- 1.23%*; BEP 5 micromol/L, 95.3 +/- 0.89%*; mean +/- SEM; *p < 0.05 vs. untreated) and 60 min of glutamate excitotoxicity (200 micromol/L; cell viability: untreated, 54.1 +/- 0.69%; BEP 1 micromol/L, 61.2 +/- 1.19%*; BEP 2.5 micromol/L, 78.1 +/- 1.67%*; BEP 5 micromol/L, 91.2 +/- 1.20%*; mean +/- SEM; *p < 0.05 vs. untreated), and inhibited the reactive oxygen species surge upon glutamate exposure. The protection was antagonized with co-application of the superoxide dismutase mimetic M40401, but not with reduced glutathione, catalase, or with the mitoK(ATP) blocker 5-hydroxydecanoate. Furthermore, BEP treatment resulted in increased levels of phosphorylated protein kinase C, manganese-dependent superoxide dismutase, glutathione peroxidase, and Bcl-2. Our results indicate that BEP induces delayed neuronal preconditioning which is dependent on superoxide generation but perhaps not on direct mitoK(ATP) activation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-3042
pubmed:author
pubmed:issnType
Print
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
595-608
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:17394552-Animals, pubmed-meshheading:17394552-Bepridil, pubmed-meshheading:17394552-Brain, pubmed-meshheading:17394552-Calcium Channel Blockers, pubmed-meshheading:17394552-Cell Survival, pubmed-meshheading:17394552-Cells, Cultured, pubmed-meshheading:17394552-Cerebral Cortex, pubmed-meshheading:17394552-Dose-Response Relationship, Drug, pubmed-meshheading:17394552-Excitatory Amino Acid Antagonists, pubmed-meshheading:17394552-Hypoxia-Ischemia, Brain, pubmed-meshheading:17394552-Ischemic Preconditioning, pubmed-meshheading:17394552-Membrane Potential, Mitochondrial, pubmed-meshheading:17394552-Neurons, pubmed-meshheading:17394552-Neuroprotective Agents, pubmed-meshheading:17394552-Organometallic Compounds, pubmed-meshheading:17394552-Protein Kinase C, pubmed-meshheading:17394552-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:17394552-Rats, pubmed-meshheading:17394552-Rats, Sprague-Dawley, pubmed-meshheading:17394552-Reactive Oxygen Species, pubmed-meshheading:17394552-Signal Transduction, pubmed-meshheading:17394552-Superoxide Dismutase
pubmed:year
2007
pubmed:articleTitle
Neuronal preconditioning with the antianginal drug, bepridil.
pubmed:affiliation
Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157-1010, USA. tgaspar@wfubmc.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural